A revolutionary mRNA-based vaccine targeting a broad spectrum of common respiratory viruses, offering unprecedented broad-spectrum protection with minimal side effects.
Utilizing a novel chimpanzee adenovirus vector, this vaccine shows promising results against emerging infectious diseases, with ongoing pre-clinical studies demonstrating strong cellular immunity.
A next-generation protein subunit vaccine designed for enhanced stability and ease of administration, currently undergoing Phase 2 trials for widespread infectious disease prevention.
A refined inactivated virus vaccine, offering a traditional yet highly effective approach to immunity against persistent pathogens, backed by robust clinical data.
An innovative DNA-based vaccine candidate exploring novel immunogenic targets. Early research suggests potential for long-lasting immunity and rapid manufacturing capabilities.
This multi-component vaccine aims to induce a potent humoral and cellular immune response against a complex set of viral targets, currently in early-stage human trials.